We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.20 | 2.08% | 9.80 | 9.80 | 9.95 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 10.40 | 9.80 | 10.20 | 2,062,567 | 15:40:22 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.90 | 57.22M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/4/2024 | 10:48 | ALNC |  e-Therapeutics says company faces lack of interest as UK listing |
| 10/4/2024 | 07:00 | UK RNS | e-Therapeutics plc Proposed Fundraise of £28.9m and Cancellation |
| 31/1/2024 | 16:30 | UK RNS | e-Therapeutics plc Total Voting Rights |
| 24/1/2024 | 10:04 | UKREG | e-Therapeutics plc Exercise of Options and Issue of Equity |
| 16/1/2024 | 10:34 | ALNC | IN BRIEF: e-Therapeutics shares rise on strong financial year |
| 16/1/2024 | 07:00 | UKREG | e-Therapeutics plc Business Update |
| 09/1/2024 | 16:04 | UKREG | e-Therapeutics plc Director Dealing and Issue of Equity |
| 27/12/2023 | 10:27 | ALNC | IN BRIEF: e-Therapeutics shares to cease trading on OTCQX |
| 27/12/2023 | 07:00 | UKREG | e-Therapeutics plc Update on OTCQX Market Listing |
| 02/11/2023 | 14:34 | ALNC | EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production |
1 Year E-therapeutics Chart |
Intraday E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
